Sen. Tammy Baldwin

Maddy summaryThis bill strengthens penalties for individuals or organizations charging veterans unauthorized fees when assisting with VA benefit claims. It directly affects veterans who might be targeted by unscrupulous representatives and the representatives themselves who attempt to charge such fees. The key provision adds a new subsection (b) to Section 5905, making it illegal to solicit, charge, or receive any fee for preparing or submitting VA claims - except as allowed under specific other sections. Violations can result in fines, up to one year in prison, or both.

Maddy summaryThis bill directs the U.S. Holocaust Memorial Museum to study how Holocaust education is implemented in all 50 states' public K-12 schools. The study will examine curriculum requirements, teacher training, teaching materials, assessment methods, and challenges in teaching about the Holocaust and antisemitism. The Museum must submit a report to Congress within 3 years of the bill's enactment detailing findings on educational practices and resource needs. This affects every state education system and public school district nationwide by mandating a comprehensive review of current Holocaust education approaches.

Maddy summaryThe Love Lives On Act of 2023 restores survivor benefits for veterans' spouses who remarried before age 55 and before the bill's enactment, which they previously lost due to remarriage. It removes an expiration date for the Marine Gunnery Sergeant John David Fry Scholarship for surviving spouses and expands access to military commissaries and exchanges for remarried surviving spouses. The bill also extends TRICARE coverage to include remarried widows or widowers whose subsequent marriage ended.

Maddy summaryThe INSULIN Act of 2023 sets cost-sharing limits for insulin products under most health insurance plans. Starting in 2024, health plans must cover selected insulin products with no deductible and cost-sharing capped at $35 per 30-day supply before 2025, and at the lesser of $35 or 25% of the negotiated price after 2025. The bill defines "selected insulin products" to include at least one of each dosage form (vial, pen, inhaler) and type (rapid-acting, short-acting, intermediate-acting, long-acting, pre-mixed) of insulin. It also requires pharmacy benefit managers to pass through 100% of insulin rebates to health plans and mandates a report on insulin market competition and barriers to biosimilar adoption. This legislation directly affects millions of people with diabetes who rely on insulin and their health insurance plans.

Maddy summaryThis bill strengthens oversight of overseas aircraft maintenance facilities by requiring U.S. airlines to annually report detailed information about heavy maintenance work performed outside the U.S. on aircraft operated under FAA Part 121. It mandates that repair stations certified under FAA Part 145 (which perform such maintenance) must have mechanics properly certified and available for consultation during work. The FAA gains expanded authority to conduct unannounced inspections of these facilities, considering both U.S. obligations and host country laws. Additionally, the bill requires FAA employees to complete alcohol/drug testing before international travel for safety-related missions, with strict reporting for any exceptions.

Maddy summaryThe SMART Prices Act changes how Medicare negotiates drug prices. It repeals a rule blocking Medicare from negotiating with drugmakers and accelerates the process, requiring negotiations for 40 drugs starting in 2027 (up from 10 annually). It shortens the time drugs must be single-source to qualify for negotiation (from 7 to 3 years) and adjusts price negotiation formulas, setting new caps like 76% of the drug's average price for some medications. This directly affects Medicare beneficiaries (by lowering their out-of-pocket costs) and pharmaceutical companies (by requiring price negotiations for more drugs faster).

Maddy summaryThe First Step Implementation Act of 2023 implements key provisions from the First Step Act of 2018 by allowing courts to reduce sentences for certain drug offenses and creating new parole options for juveniles convicted as adults. It establishes automatic sealing of juvenile nonviolent offense records after three years of completing supervision and provides a process for expungement of certain juvenile records. The bill also requires the Attorney General to implement procedures for correcting inaccurate or incomplete criminal records used in employment background checks. These provisions directly affect individuals with past juvenile offenses, those with certain drug convictions, and people seeking employment who may have inaccurate criminal records.

Maddy summaryThe SMART Prices Act (S 1246) repeals a provision blocking states from negotiating Medicare drug prices and accelerates the Medicare Drug Price Negotiation Program. It increases the annual number of drugs eligible for negotiation from 10 to 40 starting in 2027, shortens the timeframes for qualifying drugs from 7 to 3 years, and adjusts price ceiling percentages (e.g., raising the maximum fair price cap for some drugs from 75% to 76%). These changes directly affect Medicare beneficiaries by potentially lowering drug costs and pharmaceutical companies by altering negotiation timelines and pricing rules. The bill aims to reduce Medicare drug spending through faster, more aggressive price negotiations.

Maddy summaryS 1235 "Bruce's Law" creates new federal programs to address fentanyl contamination in illegal drugs. It mandates public education campaigns targeting youth, parents, schools, and first responders about the dangers of fentanyl-contaminated drugs, including prevention strategies and early warning signs of addiction. The bill establishes a Federal Interagency Work Group to coordinate efforts across health, law enforcement, and education agencies, and authorizes grants for community coalitions in areas with significant fentanyl-related overdoses to implement evidence-based prevention programs focused on youth. These provisions apply directly to communities experiencing fentanyl-related overdoses and require annual reporting to Congress on strategies to reduce overdoses.

Maddy summaryS 1250, the Drug-price Transparency for Consumers Act of 2023, requires pharmaceutical companies to disclose the wholesale acquisition cost (WAC) for a 30-day supply of prescription drugs in direct-to-consumer advertisements. This applies to drugs covered by Medicare or Medicaid, excluding those with a WAC under $35 per 30-day supply. The bill mandates clear display of the list price in ads, with manufacturers facing $100,000 penalties for noncompliance. It aims to give consumers upfront price information before they discuss prescriptions with doctors, helping them compare costs and make informed choices.